Translational Development Acquisition’s (NASDAQ:TDACU – Get Free Report) quiet period will expire on Monday, February 3rd. Translational Development Acquisition had issued 15,000,000 shares in its initial public offering on December 23rd. The total size of the offering was $150,000,000 based on an initial share price of $10.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Translational Development Acquisition Trading Down 0.1 %
Shares of TDACU opened at $10.04 on Wednesday. Translational Development Acquisition has a 52-week low of $10.00 and a 52-week high of $10.05.
Hedge Funds Weigh In On Translational Development Acquisition
A hedge fund recently bought a new stake in Translational Development Acquisition stock. Tuttle Capital Management LLC bought a new position in shares of Translational Development Acquisition Corp. (NASDAQ:TDACU – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $461,000. Translational Development Acquisition comprises approximately 2.7% of Tuttle Capital Management LLC’s investment portfolio, making the stock its 9th biggest position.
Translational Development Acquisition Company Profile
Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector.
See Also
- Five stocks we like better than Translational Development Acquisition
- 3 Fintech Stocks With Good 2021 Prospects
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is the S&P/TSX Index?
- What Does the Future Hold for Eli Lilly?
- Compound Interest and Why It Matters When Investing
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.